[Parenteral feeding. Biochemical and clinical findings during continuous long-term infusion of glucose, fructose, sorbitol and xylitol. 2. Clinical aspects, discussion and results]. 1975

H Förster, and L Heller, and U Hellmund, and S Boecker

Four groups of six volunteers were given continuous infusions of glucose, fructose, sorbitol and xylitol in a dosage of 0.25 g/kg body weight over 48 hours. All solutions were well tolerated provided that potassium was supplemented in sufficient amounts. During the first 12 hour period of xylitol infusion renal potassium loss was greater than during infusion of all other substrates. No substantial differences in the alterations of the other parameters were noted between glucose and glucose substitutes. The only exception was the rise in serum uric acid concentration during infusion of xylitol and of fructose, which was not noted during infusion of glucose or sorbitol. The concentration of serum bilirubin was elevated during infusion of all four substances. The decrease in serum free fatty acid concentration was equally caused by glucose, fructose, xylitol or sorbitol. The increase in serum triglyceride concentration was observed earlier during the infusion of glucose substitutes as compared to glucose. Blood glucose concentration was only elevated during infusion of glucose. In the post infusion period there was quick rise in fatty acid concentration after cessation of glucose infusion. This normalisation occurred more slowly after stopping fructose and particulary xylitol or sorbitol. These results have no indications for adverse effects of the continuous infusions of glucose or glucose substitutes.

UI MeSH Term Description Entries
D006996 Hypocalcemia Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed) Hypocalcemias
D007773 Lactates Salts or esters of LACTIC ACID containing the general formula CH3CHOHCOOR.
D008134 Long-Term Care Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care. Care, Long-Term,Long Term Care
D010288 Parenteral Nutrition The administering of nutrients for assimilation and utilization by a patient who cannot maintain adequate nutrition by enteral feeding alone. Nutrients are administered by a route other than the alimentary canal (e.g., intravenously, subcutaneously). Intravenous Feeding,Nutrition, Parenteral,Parenteral Feeding,Feeding, Intravenous,Feeding, Parenteral,Feedings, Intravenous,Feedings, Parenteral,Intravenous Feedings,Parenteral Feedings
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011644 Puerperal Disorders Disorders or diseases associated with PUERPERIUM, the six-to-eight-week period immediately after PARTURITION in humans. Disorder, Puerperal,Disorders, Puerperal,Puerperal Disorder
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D005632 Fructose A monosaccharide in sweet fruits and honey that is soluble in water, alcohol, or ether. It is used as a preservative and an intravenous infusion in parenteral feeding. Levulose,Apir Levulosa,Fleboplast Levulosa,Levulosa,Levulosa Baxter,Levulosa Braun,Levulosa Grifols,Levulosa Ibys,Levulosa Ife,Levulosa Mein,Levulosado Bieffe Medit,Levulosado Braun,Levulosado Vitulia,Plast Apyr Levulosa Mein,Levulosa, Apir,Levulosa, Fleboplast

Related Publications

H Förster, and L Heller, and U Hellmund, and S Boecker
September 1974, Zeitschrift fur Ernahrungswissenschaft,
H Förster, and L Heller, and U Hellmund, and S Boecker
January 1976, Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Beiheft,
H Förster, and L Heller, and U Hellmund, and S Boecker
August 1967, Klinische Wochenschrift,
H Förster, and L Heller, and U Hellmund, and S Boecker
March 1974, Deutsche medizinische Wochenschrift (1946),
H Förster, and L Heller, and U Hellmund, and S Boecker
October 1973, Die Infusionstherapie,
H Förster, and L Heller, and U Hellmund, and S Boecker
January 1985, Acta anaesthesiologica Scandinavica. Supplementum,
H Förster, and L Heller, and U Hellmund, and S Boecker
April 1976, Casopis lekaru ceskych,
H Förster, and L Heller, and U Hellmund, and S Boecker
January 1980, Metabolism: clinical and experimental,
H Förster, and L Heller, and U Hellmund, and S Boecker
January 1976, Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Beiheft,
H Förster, and L Heller, and U Hellmund, and S Boecker
September 1980, Ugeskrift for laeger,
Copied contents to your clipboard!